David Mills

David Mills

Company: Ambrx

Job title: Director, Preclinical Science


Site-Specific TLR7 Agonist Antibody-Drug Conjugates as Next Generation ADCs 1:00 pm

Presenting on the site-specific TLR7a ADC developed by EuCODE platform with an expanded genetic code Reviewing how protein medicinal chemistry enables fine-tuning of TLR7a ADC to balance potency and safety in preclinical studies Demonstrating how Ambrx’s TLR7a ADCs elicit strong anti-tumor responses as single-agent as well as in combination therapiesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.